Involvement of MMP-2 in adriamycin resistance dependent on ERK1/2 signal pathway in human osteosarcoma MG-63 cells

Abstract

Matrix metalloproteinase-2 (MMP-2) level and the ERK1/2 signal pathway are dependent factors for the growth and metastasis of cancer. However, the impact of MMP-2 in combination with ERK1/2 in tumor patients with drug resistance is unknown. To determine the relationship between MMP-2 and the ERK1/2 signal pathway, we established an adriamycin (ADM)-induced MG-63 (ADM-MG-63) cell line. With the increase of the ERK1/2 pathway blocker PD98059, we detected the expression levels of MMP-2 and p-ERK1/2 by Western blot in ADM-MG-63 cells. In ADM-MG-63 cells transfected with MMP-2-siRNA, the expression of ERK1/2 was detected for understanding the function of the ERK1/2 signal pathway. Three siRNAs for MMP-2 (MMP-2-siRNA) were designed, and the optimal one was selected and tested at different time points of 24, 48 and 72 h. Under an ADM-induced condition, ADM-MG-63 cells were finally stable living in the medium of ADM (200 ng/mL). PD98059 could effectively suppress the expression levels of p-ERK1/2 and MMP-2. When the MMP-2 was silenced by using MMP-2-siRNA, the expression of p-ERK1/2 was enhanced. It is concluded that MMP-2 may be involved in ADM resistance dependent on ERK1/2 signal pathway, suggesting interference in ERK1/2 may be a new method of targeted therapy for tumor resistance.

Keywords

adriamycin / matrix metalloproteinase-2 / osteosarcoma / RNA interference

References

[1] MarinaN., GebhardtM., TeotL., et al.. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 2004, 9(4): 422-441

[2] Cleton-JansenA.M., AnningaJ.K., Briaire-de BruijnI.H., et al.. Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer, 2009, 101(11): 1909-1918

[3] MatsubaraH., WatanabeM., ImaiT., et al.. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene -4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetra azabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone]. J Pharmacol Exp Ther, 2009, 328(3): 839-848

[4] HirotsuM., SetoguchiT., SasakiH., et al.. Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer, 2010, 9: 5-19

[5] SusaM., IyerA.K., RyuK., et al.. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer, 2009, 9: 399-411

[6] SakamotoA., IwamotoY.. Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy. Rev Recent Clin Trials, 2008, 3(3): 228-231

[7] AdyaR., TanB.K., PunnA., et al.. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signaling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res, 2008, 78(2): 356-365

[8] SéguinC.A., PilliarR.M., MadriJ.A., et al.. TNF-alpha induces MMP2 gelatinase activity and MT1-MMP expression in an in vitro model of nucleus pulposus tissue degeneration. Spine, 2008, 1533(4): 356-365

[9] SteelmanL.S., PohnertS.C., SheltonJ.G., et al.. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004, 18(2): 189-218

[10] OverallC.M., KleifeldO.. Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer, 2006, 6(3): 227-239

[11] LiQ.Q., WangW.J., XuJ.D., et al.. Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycopro tein substrates in multidrug resistant breast cancer cells. Cancer Sci, 2007, 98(11): 1767-1774

[12] SongJ.H., KimS.H., ChoD., et al.. Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2. Int J Cancer, 2009, 125(5): 1074-1081

[13] LiangY., O’DriscollL., McDonnellS., et al.. Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer, 2004, 111(4): 484-493

[14] Di SimoneN., Di NicuoloF., SanguinettiM., et al.. Resistin regulates human choriocarcinoma cell invasive behavior and endothelial cell angiogenic processes. J Endocrinol, 2006, 189(3): 691-699

[15] JunttilaM.R., LiS.P., WestermarckJ., et al.. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J, 2008, 22(4): 954-965

[16] MontagutC., SettlemanJ.. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett, 2009, 283(2): 125-134

[17] HsiehY.S., ChuS.C., YangS.F., et al.. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis, 2007, 28(5): 977-987

[18] BanerjiA., DasS., ChatterjeeA., et al.. Culture of human A375 melanoma cells in the presence of fibronectin causes expression of MMP-9 and activation of MMP-2 in culture supernatants. J Environ Pathol Toxicol Oncol, 2008, 27(2): 135-145